Quality of care indicators for gout management.

OBJECTIVE Despite the significant health impact of gout, there is no consensus on management standards. To guide physician practice, we sought to develop quality of care indicators for gout management. METHODS A systematic literature review of gout therapy was performed using the Medline database. Two abstractors independently reviewed each of the articles for relevance and satisfaction of minimal inclusion criteria. Based on the review of the literature, 11 preliminary quality indicators were developed and then reviewed and refined by an initial feasibility panel of community and academic rheumatologists. A twelfth indicator was added at the request of the first panel. Using a modification of the RAND/University of California at Los Angeles appropriateness method (bridging teleconference and white-board Internet technology were added), a second expert panel rated each of the proposed indicators for validity using a 9-point scale, in which ratings of 1-3, 4-6, and 7-9 were considered "invalid," "indeterminate," and "highly valid," respectively. Indicators were considered valid if the median panel rating was > or =7 and there was no evidence of panel disagreement (defined to occur when 2 of 6 panelists provided a validity rating of 1-3 and 2 panelists provided a validity rating of 7-9). RESULTS Ten of the 12 draft indicators were rated to be valid by our second expert panel. Validated indicators pertained to 1) the use of urate-lowering medications in chronic gout, 2) the use of antiinflammatory drugs, and 3) counseling on lifestyle modifications. CONCLUSION Using a combination of evidence and expert opinion, 10 indicators for quality of gout care were developed. These indicators represent an important initial step in quality improvement initiatives for gout care.

[1]  G. Peterson,et al.  Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy , 2004, European Journal of Clinical Pharmacology.

[2]  G. Fonarow Quality Indicators for the Management of Heart Failure in Vulnerable Elders , 2001, Annals of Internal Medicine.

[3]  C. MacLean Quality Indicators for the Management of Osteoarthritis in Vulnerable Elders , 2001, Annals of Internal Medicine.

[4]  J. Schnelle,et al.  Quality Indicators for the Management of Urinary Incontinence in Vulnerable Community-Dwelling Elders , 2001, Annals of Internal Medicine.

[5]  Paul Shekelle,et al.  Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators , 2001, Annals of Internal Medicine.

[6]  B. Bates-Jensen Quality Indicators for Prevention and Management of Pressure Ulcers in Vulnerable Elders , 2001, Annals of Internal Medicine.

[7]  C. MacLean,et al.  Quality Indicators for the Management of Osteoporosis in Vulnerable Elders , 2001, Annals of Internal Medicine.

[8]  T. Chow,et al.  Quality Indicators for Dementia in Vulnerable Community-Dwelling and Hospitalized Elders , 2001, Annals of Internal Medicine.

[9]  C. Benesch,et al.  Development of Performance Measures for Acute Ischemic Stroke , 2001, Stroke.

[10]  P. Friedmann,et al.  Appropriateness of medication selection for older persons in an urban academic emergency department. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[11]  W. Braun,et al.  The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. , 1999, Transplantation proceedings.

[12]  J P Kahan,et al.  The reproducibility of a method to identify the overuse and underuse of medical procedures. , 1998, The New England journal of medicine.

[13]  L. E. Peterson,et al.  Eliciting expert opinion using the Delphi technique: identifying performance indicators for cardiovascular disease. , 1998, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[14]  P. Shekelle,et al.  Assessing the Predictive Validity of the RAND/UCLA Appropriateness Method Criteria for Performing Carotid Endarterectomy , 1998, International Journal of Technology Assessment in Health Care.

[15]  D. Gifford,et al.  Development of a quality of care measurement system for children and adolescents. Methodological considerations and comparisons with a system for adult women. , 1997, Archives of pediatrics & adolescent medicine.

[16]  E. Thervet,et al.  Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. , 1997, Transplantation.

[17]  M A Hlatky,et al.  Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. , 1996, The New England journal of medicine.

[18]  K. Wegscheider,et al.  Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. , 1996, The Journal of rheumatology.

[19]  Sanders Km,et al.  A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. , 1996 .

[20]  P. Pillans,et al.  A survey of allopurinol dosage prescribing. , 1995, The New Zealand medical journal.

[21]  R. Kravitz,et al.  Validity of criteria used for detecting underuse of coronary revascularization. , 1995, JAMA.

[22]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[23]  C M Ashton,et al.  A Method of Developing and Weighting Explicit Process of Care Criteria for Quality Assessment , 1994, Medical care.

[24]  L. Leape,et al.  Coronary angiography and revascularization: defining procedural indications through formal group processes. The Canadian Revascularization Panel, the Canadian Coronary Angiography Panel. , 1994, The Canadian journal of cardiology.

[25]  J. Devlin,et al.  Observations and effects of educational consults on allopurinol prescribing. , 1992, The Canadian journal of hospital pharmacy.

[26]  G. Mccarthy,et al.  Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. , 2010, Arthritis and rheumatism.

[27]  H. Cheung,et al.  The mitogenic response to stimulation with basic calcium phosphate crystals is accompanied by induction and secretion of collagenase in human fibroblasts. , 1991, Arthritis and rheumatism.

[28]  R. Kuncl,et al.  Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. , 1991, The Journal of rheumatology.

[29]  V. Sharman,et al.  Azathioprine and allopurinol: a potentially dangerous combination , 1990, Journal of internal medicine.

[30]  Bullock Pw,et al.  Intermittent control of hyperuricemia in the treatment of gout. , 1989 .

[31]  R. Day,et al.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. , 1988, British journal of clinical pharmacology.

[32]  S. Ralston,et al.  Alcohol and response to treatment of gout , 1988, British medical journal.

[33]  Wallace Sl,et al.  Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use. , 1988 .

[34]  J. Levin,et al.  Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.

[35]  R. Fraser,et al.  Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. , 1987, The Journal of the Royal College of General Practitioners.

[36]  P. Brooks,et al.  Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.

[37]  S. Wallace,et al.  The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. , 1986, Arthritis and rheumatism.

[38]  J. Scott,et al.  Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. , 1985, British journal of clinical pharmacology.

[39]  P. Fritsch,et al.  Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. , 1985, British medical journal.

[40]  A. Wade,et al.  Clinical Experience with Isoxicam in Patients with Acute Gout , 1985, The British journal of clinical practice.

[41]  U. Deesomchok,et al.  Piroxicam in treatment of acute gout high dose versus low dose. , 1985, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[42]  Karachalios Gn Treatment of acute gouty arthritis with piroxicam. , 1985 .

[43]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.

[44]  R. Eberl,et al.  Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. , 1983, Arzneimittel-Forschung.

[45]  H. Simmonds,et al.  Allopurinol treatment and its effect on renal function in gout: a controlled study. , 1982, Annals of the rheumatic diseases.

[46]  G. Mcinnes,et al.  Acute adverse reactions attributed to allopurinol in hospitalised patients. , 1981, Annals of the rheumatic diseases.

[47]  J. Zazgornik,et al.  Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. , 1981, International journal of clinical pharmacology, therapy, and toxicology.

[48]  J. Scott,et al.  Acute gout during hypouricaemic therapy: prophylaxis with colchicine. , 1980, Annals of the rheumatic diseases.

[49]  G. Sacchetti,et al.  Intravenous Indoprofen for Prompt Relief of Acute Gout: A Regimen-Finding Study , 1980, The Journal of international medical research.

[50]  J. Klinenberg,et al.  Benzbromarone as a long-term uricosuric agent. , 1980, Advances in experimental medicine and biology.

[51]  H. Simmonds,et al.  A controlled study of the effect of long term allopurinol treatment on renal function in gout. , 1980, Advances in experimental medicine and biology.

[52]  J. Scott,et al.  Double-blind trial of feprazone and phenylbutazone in acute gout. , 1980, Current medical research and opinion.

[53]  F. Matzkies,et al.  The action of benzbromarone in relation to age, sex and accompanying diseases. , 1980, Advances in experimental medicine and biology.

[54]  G. Elion,et al.  Studies with allopurinol in patients with impaired renal function. , 1980, Advances in experimental medicine and biology.

[55]  J. E. Murphy Piroxicam in the Treatment of Acute Gout: A Multicentre Open Study in General Practice , 1979, The Journal of international medical research.

[56]  G. Lupton,et al.  The allopurinol hypersensitivity syndrome. , 1979, Journal of the American Academy of Dermatology.

[57]  W. Fessel Renal outcomes of gout and hyperuricemia. , 1979, The American journal of medicine.

[58]  H. Rubinstein,et al.  Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. , 1979, Arthritis and rheumatism.

[59]  D. Nashel,et al.  Ibuprofen in the treatment of acute gouty arthritis. , 1978, JAMA.

[60]  A. Ruotsi,et al.  Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. , 1978, Scandinavian journal of rheumatology. Supplement.

[61]  O. Khoo,et al.  Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. , 1977, Australian and New Zealand journal of medicine.

[62]  T. Reynolds,et al.  Allopurinol-hypersensitivity vasculitis and liver damage. , 1977, The Western journal of medicine.

[63]  J. Scott,et al.  Multi-centre trial of naproxen and phenylbutazone in acute gout. , 1977, Advances in experimental medicine and biology.

[64]  Yu Tf Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. , 1976 .

[65]  Y. Lertratanakul,et al.  Effect of fenoprofen calcium on acute gouty arthritis. , 1976, Arthritis and rheumatism.

[66]  D. Levinson,et al.  Clinical evaluation of benzbromarone: a new uricosuric drug. , 1976, Arthritis and rheumatism.

[67]  C. Smyth,et al.  The influence of allopurinol on renal function in gout. , 1975, Arthritis and rheumatism.

[68]  J. Scott,et al.  Single daily dose of allopurinol. , 1975, Annals of the rheumatic diseases.

[69]  S. Tolchin,et al.  Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. , 1975, JAMA.

[70]  J. Young,et al.  Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. , 1974, Archives of internal medicine.

[71]  Robert G. Godfrey,et al.  Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.

[72]  J. Scott,et al.  Withdrawal of allopurinol in patients with gout. , 1974, Advances in experimental medicine and biology.

[73]  F. Delbarre,et al.  Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. , 1974, Advances in experimental medicine and biology.

[74]  J. Rosenfeld,et al.  Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. , 1974, Advances in experimental medicine and biology.

[75]  J. Case,et al.  The Treatment of Acute Gout with Naproxen , 1975, Scandinavian journal of rheumatology. Supplement.

[76]  C. Smyth,et al.  Comparison of indomethacin and phenylbutazone in acute gout. , 1973, Annals of the rheumatic diseases.

[77]  P. Cuq Experience Francaise Du Traitement De La Crise De Goutte Aigue Par Le Naproxen - C 1674 , 1973 .

[78]  J. Scott,et al.  Effect of weight-loss on plasma and urinary levels of uric acid. , 1972, Lancet.

[79]  R. Mills Severe hypersensitivity reactions associated with allopurinol. , 1971, JAMA.

[80]  R. Grahame,et al.  Clinical survey of 354 patients with gout. , 1970, Annals of the rheumatic diseases.

[81]  M. Thompson,et al.  A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. , 1970, Annals of physical medicine.

[82]  J. Davis Safety and effectiveness of colchicine by intravenous administration in the treatment of gout. , 1969, The Journal of clinical pharmacology and the journal of new drugs.

[83]  G. Hitchings,et al.  Renal clearance of oxipurinol, the chief metabolite of allopurinol. , 1968, The American journal of medicine.

[84]  C. Reed,et al.  Lead in dringking water. , 1967, Lancet.

[85]  B. Emmerson Regimen of indomethacin therapy in acute gouty arthritis. , 1967, British medical journal.

[86]  H. Simmonds,et al.  Allopurinol in the treatment of uraemic patients with gout. , 1967, Annals of the rheumatic diseases.

[87]  B. Amor,et al.  Treatment of Gout with Allopurinol , 1966, Annals of the rheumatic diseases.

[88]  J. Scott,et al.  Session II: Primary Hyperuricaemia and Gout , 1966 .

[89]  R. P. Glover,et al.  Treatment of Gout with Allopurinol and Sulphinpyrazone in Combination and with Allopurinol Alone* , 1966, Annals of the rheumatic diseases.

[90]  J. Houpt The effect of allopurinol (HPP) in the treatment of gout. , 1965, Arthritis and rheumatism.

[91]  C. Smyth Studies with allopurinol (HPP) in patients with tophaceous gout. , 1965, Arthritis and rheumatism.

[92]  T. Yü,et al.  The effect of allopurinol in primary and secondary gout. , 1965, Arthritis and rheumatism.

[93]  J. Seegmiller,et al.  THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT. , 1965, Annals of internal medicine.

[94]  P. Boardman,et al.  208.--INDOMETHACIN IN THE TREATMENT OF ACUTE GOUT. , 1965, The Practitioner.

[95]  A. Gutman,et al.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.

[96]  J. Scott,et al.  4-Hydroxypyrazolo (3,4-d) Pyrimidine (HPP) in the Treatment of Gout , 1964, Annals of the rheumatic diseases.

[97]  Rw Rundres Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout , 1963 .

[98]  R. Persellin,et al.  The use of sulfinpyrazone in the treatment of gout. , 1961, JAMA.

[99]  L. Carmichael Treatment of acute gout with injection of colchicine. , 1959, Journal of the American Medical Association.

[100]  A. Gutman,et al.  Protracted uricosuric therapy in tophaceous gout. , 1957, Lancet.

[101]  J. Davis,et al.  The effect of intravenous colchicine on acute gout. , 1954, The American journal of medicine.

[102]  R. Schaffarzick,et al.  Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. , 1952, Journal of the American Medical Association.

[103]  J. Talbott,et al.  The clinical and metabolic effects of benemid in patients with gout. , 1951, Transactions of the Association of American Physicians.